P
ProBio
Provides end-to-end CDMO service from drug discovery to commercialization
About ProBio
GenScript ProBio is a biotechnology company that operates as a Contract Development and Manufacturing Organization (CDMO). In simpler terms, it provides end-to-end services to other companies in the biopharma industry, helping them develop and manufacture drugs. The company specializes in Cell and Gene Therapy (CGT), vaccines, and antibody protein drugs.
Read full description
GenScript ProBio serves a global clientele, with established companies in the United States, the Netherlands, South Korea, and China. Since October 2017, it has helped clients in the United States, Europe, and Asia Pacific obtain over 50 Investigational New Drug (IND) approvals. IND approval is a necessary step for a company to start clinical trials on humans for a new drug.
The company's business model revolves around offering flexible solutions for different stages of drug development, from discovery to commercialization. It boasts a unique Phase-appropriate Compliance (PAC) quality system, which ensures its services meet stringent regulatory standards worldwide. This system benefits customers by providing high-quality, cost-effective, and efficient solutions.
GenScript ProBio generates revenue by charging for its services, which include the development of biological products, regulatory support, and manufacturing capacity. The company plans to expand its bioreactor capacity to 16,800 liters by 2023, which will enable it to handle up to 20 CGT IND and 400 L biologics.
At a glance
- Status
- Operational
- Founded
- 2002
- Headquarters
- Nanjing City, China
- Employees
- 242
- Open positions
- None listed
- Dealroom signal
- 53.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Rumoured $1B, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning ProBio.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jan 2023 | $220M | $880M | Hillhouse Capital · New Alliance Capital · Highlight Capital · Xiamen C&D | ↗ |
Growth signals
Latest recorded traffic for ProBio is 18K monthly website visits, up 1400% over the last three months. ProBio's team grew 9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later7 investors entered at this stage
Legend Capital
Hillhouse Capital
New Alliance Capital
Highlight Capital
Xiamen C&D- GIGF Xinde Investment
Huatai Zijin Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ProBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ProBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.